Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Diagnostics & Research

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

Revenue projections:

Revenue projections for TMO
Revenue projections for TMO

TMO is projected to see lower revenues than in the previous year, a trend that usually concerns investors. Declining revenues often harm a company's profitability, leading investors to exercise caution as they weigh the potential risks of continued financial downturns.

Financial Ratios:

currentRatio 1.52600
forwardPE 16.71198
debtToEquity 82.90300
earningsGrowth 0.11300
revenueGrowth 0.06200
grossMargins 0.40932
operatingMargins 0.17892
trailingEps 18.52000
forwardEps 27.29838

TMO's current ratio of 1.526 shows that the company has ample resources to service its short-term debt. This indicates a solid financial position, as TMO can rely on its cash reserves and current assets to cover its immediate liabilities without strain.
TMO's Forward PE is at a healthy level, meaning the stock price is aligned favorably with earnings. This suggests that the stock isn't overpriced, providing room for growth and making it an appealing option for investors looking to capitalize on potential future gains.
Thermo Fisher Scientific Inc.'s high debt-to-equity ratio indicates the company is using significant leverage, relying more on debt to finance its operations. This can lead to higher risk, especially if profitability falters or economic conditions worsen.
With a forward EPS greater than its trailing EPS, TMO is expected to see higher profitability this year. The forecasted increase in earnings reflects optimism about the company's financial growth and potential for improved performance over the prior year.

Price projections:

Price projections for TMO
Price projections for TMO

Over time, TMO's price projections have steadily declined, reflecting reduced confidence in the company's future performance. The downward revisions suggest analysts are becoming more conservative in their assessments.

Insider Transactions:

Insider Transactions for TMO
Insider Transactions for TMO


There were 23 transactions selling TMO stock, with prevailing market price of 525.855724832286.During the period under consideration, there were no sell transactions.The trend of more buys compared to sells around Thermo Fisher Scientific Inc.'s current price levels may signal investor optimism. This behavior suggests that the market is expecting a favorable outcome for the stock, leading to increased buying activity.

Recommendation changes over time:

Recommendations trend for TMO
Recommendations trend for TMO


Analysts have maintained a buy bias for TMO, which could prompt investors to consider the stock as a viable investment. With this positive outlook, TMO is positioned as an attractive option for those looking to park their money in a stable and potentially lucrative company.